Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In patients with acute, uncomplicated rhinosinusitis lasting ⩾7 days, what is the relative effectiveness of mometasone furoate nasal spray, amoxicillin, and placebo?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★☆☆ Respirology ★★★★★☆☆
randomised controlled trial.
unclear allocation concealment.*
blinded (patients and healthcare providers).*
Follow up period:
up to 29 days.
71 medical centres in 14 countries.
981 patients ⩾12 years of age (mean age 35 y, 66% women) with signs and symptoms of acute rhinosinusitis for ⩾7 days but ⩽28 days and major symptom score (MSS) ⩾5 but ⩽12, with ⩽3 of 5 symptoms rated as severe (based on the sum of scores for rhinorrhoea, postnasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness).
mometasone furoate nasal spray, 200 μg, once daily for 15 days (n = 243); mometasone spray, 200 μg, twice daily for 15 days (n = 235); amoxicillin, 500 mg, …
Dr E O Meltzer
Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA.
Source of funding: Schering-Plough Research Institute.
Reproduced with permission from Evidence-Based Medicine 2006;11:114